Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

245 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer.
Weickhardt AJ, Price TJ, Chong G, Gebski V, Pavlakis N, Johns TG, Azad A, Skrinos E, Fluck K, Dobrovic A, Salemi R, Scott AM, Mariadason JM, Tebbutt NC. Weickhardt AJ, et al. Among authors: dobrovic a. J Clin Oncol. 2012 May 1;30(13):1505-12. doi: 10.1200/JCO.2011.38.6599. Epub 2012 Mar 12. J Clin Oncol. 2012. PMID: 22412142 Clinical Trial.
Fc-γ Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer.
Liu G, Tu D, Lewis M, Cheng D, Sullivan LA, Chen Z, Morgen E, Simes J, Price TJ, Tebbutt NC, Shapiro JD, Jeffery GM, Mellor JD, Mikeska T, Virk S, Shepherd LE, Jonker DJ, O'Callaghan CJ, Zalcberg JR, Karapetis CS, Dobrovic A. Liu G, et al. Among authors: dobrovic a. Clin Cancer Res. 2016 May 15;22(10):2435-44. doi: 10.1158/1078-0432.CCR-15-0414. Clin Cancer Res. 2016. PMID: 27179112 Clinical Trial.
Germline polymorphisms as biomarkers of tumor response in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a systematic review and meta-analysis.
Morgen EK, Lenz HJ, Jonker DJ, Tu D, Milano G, Graziano F, Zalcberg J, Karapetis CS, Dobrovic A, O'Callaghan CJ, Liu G. Morgen EK, et al. Among authors: dobrovic a. Pharmacogenomics J. 2017 Dec;17(6):535-542. doi: 10.1038/tpj.2016.56. Epub 2016 Nov 29. Pharmacogenomics J. 2017. PMID: 27897268 Free PMC article. Review.
Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer.
Shepshelovich D, Townsend AR, Espin-Garcia O, Latifovic L, O'Callaghan CJ, Jonker DJ, Tu D, Chen E, Morgen E, Price TJ, Shapiro J, Siu LL, Kubo M, Dobrovic A, Ratain MJ, Xu W, Mushiroda T, Liu G. Shepshelovich D, et al. Among authors: dobrovic a. Cancer Med. 2018 Nov;7(11):5478-5487. doi: 10.1002/cam4.1819. Epub 2018 Oct 14. Cancer Med. 2018. PMID: 30318772 Free PMC article. Clinical Trial.
BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.
Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, Dobrovic A, Birrer MJ, Webb PM, Stewart C, Friedlander M, Fox S, Bowtell D, Mitchell G. Alsop K, et al. Among authors: dobrovic a. J Clin Oncol. 2012 Jul 20;30(21):2654-63. doi: 10.1200/JCO.2011.39.8545. Epub 2012 Jun 18. J Clin Oncol. 2012. PMID: 22711857 Free PMC article.
245 results